SeraGene Therapeutics is developing novel siRNA therapies for patients with coagulation disorders, including bleeding and thrombosis. siRNAs are small RNA molecules that switch off specific genes, blocking the production of harmful proteins that drive disease. Thrombotic diseases contribute to one in four deaths globally and are caused by thromboinflammation  –  a pathological process in which coagulation and inflammation reinforce one another through a positive feedback loop.  

Thromboinflammation plays a central role in the development of thrombosis in many disorders, such as cancer, cardiovascular diseases, diabetes, infection and obesity. Despite its importance, current approved and investigational therapies primarily target coagulation alone and do not adequately manage the inflammatory drivers underlying this process, leaving a significant unmet medical need. 

 This project focuses on developing siRNA therapeutics that reduce the levels of fibrinogen, a key protein involved in both coagulation and inflammation. Unlike currently available therapies, these novel siRNA therapeutics have the potential to simultaneously address the dual coagulation and inflammation drivers of  thromboinflammation.  

In collaboration with Dr. Marcel Bally at BC Cancer, this project will accelerate the technical development of SeraGene’s siRNA platform,  advancing it toward a critical value inflection point and further de-risking the technology for future clinical and commercial development.